business news
(MRK) Community Analysis from
Bulls REASONS TO BUY
|
82%
agree
145 votes
|
HPV vaccine Gardasil has potential to be widely adopted |
|
66%
agree
27 votes
|
Merck acquisition of Schering-Plough strengthens Merck pipeline |
|
62%
agree
8 votes
|
The recent approval of Januvia gives a strong boost for the company |
Bears REASONS TO SELL
|
68%
agree
106 votes
|
Drug development is costly and its success is inherently risky |
|
12%
agree
8 votes
|
Large Debt Load with S/P Acq. |
|
31%
agree
16 votes
|
The aftermath of Vioxx looks bleak |
May 19, 2013
(Stock Blog Hub,
5/14/13)
Merck & Co. Inc. (MRK) recently joined forces with Bristol-Myers Squibb (BMY) to conduct a phase II study with their hepatitis C virus...(read more)
(Wealth Daily,
2/15/13)
Major biotech Merck (NYSE: MRK) has increased its investment promise for small biotech Lycera, a company researching autoimmune disease drugs...
(Stock Blog Hub,
12/23/12)
Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging agent [18F (flutemetamol)] in the development of Merck’s...(read more)
Merck (MRK) Company Overview
Merck & Co. (NYSE:MRK) is one of the largest pharmaceutical companies in the world, producing a wide assortment of medications. The company bought Schering-Plough (SGP) in 2009 to become one of the three largest pharmaceutical companies.
Merck faces many of the challenges that face all pharmaceutical companies, including issues surrounding patent expiration and FDA approval. In addition, there is growing pressure in the US and abroad to lower the price of medication. [1]
(Read more at Wikinvest
) What's in this MRK analysis on Wikinvest...
- Corporate Overview
- Company History
- Business Segments
- Bone, Respiratory, Immunology and Dermatology (24.6% of 2010 Revenues)
- Cardiovascular (10% of 2010 Revenues)
- Diabetes and Obesity (7% of 2010 Revenues)
- Diversified Brands (9% of 2010 Revenues)
- Infectious Diseases (9% of 2010 Revenues)
- Oncology (4% of 2010 Revenues)
- Vaccines (7.6% of 2010 Revenues)
- Consumer Health Care ($1.3B in total sales for 2010)
- Research and Development ($11B on 2010)
- Trends and Forces
- Merck BioVentures
- Patent expirations
- Tightening FDA Regulations
- Litigation
- Comparison to Competitors
- References
-
Stay Connected
-
-
-
-
WHAT'S POPULAR IN THE VILLE
Financial Product Guide
